Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Exclusion Criteria

• •Pregnancy or breastfeeding
• •Experienced a serious adverse drug reaction with confirmatory relationship to Tovaxin in the TERMS study.
• •Withdrew from TERMS study and did not continue participating in the remaining 52-week core TERMS study assessments.
• •Non-compliant with TERMS study.
• •Diagnosis of progressive-relapsing, secondary progressive or primary progressive Multiple Sclerosis (MS) while enrolled in the TERMS study.
• •Medical, psychiatric or other conditions that compromise the subject's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study.
• •Any significant change in the subject's medical condition after enrollment in the TERMS study which would have lead to his/her exclusion from participation in that study.